Safety and Efficacy of Donor Lymphocyte Infusions following Mismatched Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1295-1301

  Or, R ^a   Hadar, Eran ^a   Bitan, M ^a   Resnick, I B ^a   Aker, M ^a   Ackerstein, A ^a   Samuel, S ^a   Tsirigotis, P ^a   Gesundheit, B ^a   Slavin, S ^a   Shapira, M Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Donor lymphocyte infusion; Graft versus host disease; Graft versus leukemia effects; Mismatched; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HODGKIN DISEASE; HUMAN; LYMPHOCYTE TRANSFUSION; MALE; MISMATCHED STEM CELL TRANSPLANTATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; REMISSION; RISK FACTOR; STEM CELL TRANSPLANTATION; T CELL DEPLETION; TUMOR VOLUME;

EID: 33845270599     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.014     Document Type: Article

References (33)

1. Beatty P.G., Mori M., and Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60 (1995) 778-783
2. Beatty P.G., Boucher K.M., Mori M., and Milford E.L. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol 61 (2000) 834-840
3. Slavin S., Or R., Naparstek E., et al. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders. Transplant Proc 19 (1987) 2614-2615
4. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-vs-host disease in human recipients of marrow from HLA-matched-sibling donors. Transplantation 18 (1974) 295-304
5. Pugatsch T., Oppenheim A., and Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 17 (1996) 273-275
6. Nakamura Y., Leppert M., O'Connell P., et al. Variable number of tandem repeats (VNTR) markets for human gene mapping. Science 235 (1987) 1616-1622
7. Johnson P.R., and Hersey P. Anti-leukaemia activity as a bystander effect of graft-versus-host reactions. Br J Cancer 33 (1976) 370-378
8. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300 (1979) 1068-1073
9. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., and Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304 (1981) 1529-1533
10. Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., and Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23 (1995) 1553-1562
11. Kolb H.J., Schattenberg A., Goldman J.M., et al., European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
12. Raiola A.M., Van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 31 (2003) 687-693
13. Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15 (1997) 433-444
14. Kawano Y., Takaue Y., Watanabe A., et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 92 (1998) 3123-3130
15. Klingebiel T., Handgretinger R., Lang P., Bader P., and Niethammer D. Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev 18 (2004) 181-192
16. Lee C.K., deMagalhaes-Silverman M., Hohl R.J., et al. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Bone Marrow Transplant 31 (2003) 121-128
17. Diez-Martin J.L., Gomez-Pineda A., Serrano D., Carrion R., Balsalobre P., and Buno I. Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect. Bone Marrow Transplant 33 (2004) 1037-1041
18. Wu B.Y., Guo K.Y., Song C.Y., Yang D.A., and Li D. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation. Bone Marrow Transplant 26 (2000) 691-693
19. Pati A.R., Godder K., Lamb L., Gee A., and Henslee-Downey P.J. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 15 (1995) 979-981
20. Naparstek E., Or R., Nagler A., et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89 (1995) 506-515
21. Naparstek E., Nagler A., Or R., Kapelushnik J., and Slavin S. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Clinical Transplants Volume 12 (1996) 281-290
22. Wang J., Shaw J.L., and Mullen C.A. Down-regulation of antihost alloreactivity after bone marrow transplant permits relapse of hematological malignancy. Cancer Res 62 (2002) 208-212
23. Kleinclauss F., Perruche S., Masson E., et al. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ 13 (2006) 41-52
24. Raanani P., Dazzi F., Sohal J., et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99 (1997) 945-950
25. Morecki S., Yacovlev E., Gelfand Y., Uzi I., and Slavin S. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 24 (2001) 114-121
26. Slavin S., Ackerstein A., Morecki S., Gelfand Y., and Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes. Bone Marrow Transplant 28 (2001) 795-798
27. Slavin S., Shapira M., Morecki S., et al., American Society of Clinical Oncology (ASCO). Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation. New Orleans, Louisiana, USA. June 3-8, 2004. Am Soc Clin Oncol 23 (2004) 560 Abstract 6516
28. Falkenburg J.H.F., Faber L.M., van den Elshout M., et al. Generation of donor derived antileukemic cytotoxic T lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA identical bone marrow transplantation. J Immunother 14 (1993) 305-309
29. Slavin S., Shapira M.Y., Morecki S., et al. Immunotherapy for resistant hematologic malignancies using matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ after allogeneic stem cell transplantation for allogeneic cell therapy without GVHD. Blood 102 (2003) 400b Abstract 5329
30. Ackerstein A., Morecki S., Gelfand Y., Samuel S., Or R., and Slavin S. Outpatient non-myeloablative cell-mediated immunotherapy with intentionally mismatched allogeneic lymphocytes with rIL-2 for patients with metastatic solid tumors. Blood 102 (2003) 409b Abstract 5366
31. Weiss L., Reich S., and Slavin S. The role of non-activated and rIL-2 activated CD4+ and CD8+ T cells in immunotherapy for leukemia. Cytokines Cell Mol Ther 5 (1999) 153-158
32. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
33. Morecki S., Lindhofer H., Yacovlev E., Gelfand Y., and Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 107 (2006) 1564-1569